HeartSciences Inc. announced that the University of the West of England (UWE) has selected the company’s MyoVista Insights platform and MyoVista wavECG device as the exclusive ECG technologies for its new Reference Center for ECG Education and Technology. The partnership will deploy the MyoVista Insights and wavECG systems across UWE’s cardiac and physiological science teaching programs, training students in advanced quantitative ECG analysis and supporting research initiatives.
The move creates a national reference site that will validate HeartSciences’ AI‑powered ECG solutions in an academic setting and provides a strategic entry point into the National Health Service (NHS). By embedding its technology into the training of future NHS cardiac scientists, the company gains credibility and a potential pipeline for broader clinical adoption by NHS trusts.
HeartSciences has yet to generate meaningful revenue in its most recent fiscal quarters. The company reported no revenue for the first and second quarters of fiscal 2026, and its cash and cash equivalents stood at approximately $2.8 million and $2.0 million, respectively. Despite the lack of commercial sales, the company has secured FDA Breakthrough Device Designation for its aortic stenosis ECG algorithm and has submitted the MyoVista wavECG device for FDA clearance, indicating progress on the regulatory front.
CEO Andrew Simpson said, “We are delighted that UWE has selected HeartSciences to establish an ECG Education and Technology Reference Center. Training the next generation of NHS cardiac scientists on MyoVista Insights not only reinforces the clinical and educational value of our platform but also creates a strategically important reference site that supports our broader commercial engagement with the NHS in the UK.”
The partnership comes at a time when the global AI‑ECG market is projected to grow from $1.40 billion in 2024 to $9.85 billion by 2035, a compound annual growth rate of nearly 19.4%. HeartSciences’ focus on leveraging artificial intelligence to extract additional diagnostic information from ECG signals positions it to capture a share of this expanding market. The UWE collaboration also differentiates the company from competitors that rely on conventional ECG technology, giving HeartSciences a competitive edge in both academic and clinical settings.
With the academic reference center in place, HeartSciences is poised to accelerate its commercialization strategy in the UK. The partnership provides a validation platform that can be leveraged in future discussions with NHS trusts, potentially opening a pathway to nationwide deployment of its AI‑enabled ECG solutions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.